Deals
BioMarin Breaks Out $287.7 Million In Drug-Buying Costs, With A $70.0 Million Charge Still To Come
The rare-disease drugmaker now books acquired pipeline spending apart from R&D, and the October Fabry license adds to the fourth quarter.
BioMarin Pharmaceutical (BMRN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Deals
The rare-disease drugmaker now books acquired pipeline spending apart from R&D, and the October Fabry license adds to the fourth quarter.
Earnings
The CFO blamed order timing, not patient demand, and said Middle East conflict is straining customer cash flow.
Deals
The rare-disease drugmaker cut its full-year adjusted EPS forecast from $4.90-$5.10 after two acquired-research charges and a delayed international order.
Earnings
The company put a $1.55 per-share hit on the full year and said new guidance will come with third-quarter results.